Zurich – In the past year, five new spin-offs have emerged from research at the University of Zurich. They are developing new approaches for autoimmune diseases, lead poisoning, blood cancer, endometriosis and oral health diagnostics.
The five new spin-offs from the University of Zurich, which were created in 2023, are based on research work in medicine, dentistry and chemistry, according to a press release. Dentexion GmbH, for example, is working on a software platform that allows dentists to analyze and document 3D data from patient scans using artificial intelligence. This should help to evaluate changes in teeth, gums and bones over time and detect them at an early stage.
metaLead Therapeutics AG has developed novel, short peptides that overcome the disadvantages of conventional therapies for severe lead poisoning. Over 90 percent of diagnosed cases remain untreated. The leading drug candidate tested in animal models significantly reduced lead levels in the blood, brain and liver.
ATLyphe AG develops antibodies to stimulate immune cells. The current main project focuses on an antibody that activates T cells to fight acute myeloid leukemia. A Phase I trial will begin soon.
FimmCyte is researching an antibody therapy for endometriosis with the aim of replacing the usual hormone treatments and operations. The antibodies developed by the start-up recognize a specific protein that is excessively present in endometriosis cells. This enables direct treatment of the affected tissue.
Seito Biologics AG uses so-called Treg cell engagers to regulate the immune system in autoimmune diseases. They aim to keep regulatory T cells (Treg cells) in check. This therapy is intended to replace conventional treatments that suppress the immune system and thus increase the risk of infection and cancer. ce/mm